Tesamorelin (Growth Hormone-Releasing Peptide)

Tesamorelin is a synthetic peptide that stimulates the pituitary gland to release growth hormone by mimicking growth hormone-releasing hormone (GHRH). It is an FDA-approved prescription medication in the United States for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is also researched for its effects on body composition and metabolism.

Potential Benefits

• Abdominal Fat Reduction: Can reduce visceral abdominal fat in its approved medical use.
• Growth Hormone Stimulation: Encourages the body’s natural release of growth hormone.
• Body Composition: Investigated for its potential effects on body fat distribution.
• Metabolic Research: Studied for its effects on fat metabolism and related metabolic markers.
• Cognitive Research: Investigated for potential effects on certain aspects of cognitive function, with further research needed.

Possible Side Effects

• Injection-Site Reactions: Redness, itching, swelling or discomfort at the injection site.
• Fluid Retention: May cause swelling, joint pain or muscle discomfort.

Approved medical dosing: The US-approved regimen for adults with HIV-associated lipodystrophy is 2 mg injected subcutaneously once daily.